Indaptus Therapeutics — Third Quarter 2026 Earnings Summary

Indaptus Therapeutics reported a net loss of $1.0 million for the third quarter of 2026, a significant decrease from $3.0 million in the same period of 2025, driven by reduced research and development and general administrative expenses. The company completed a private placement in September 2026, raising approximately $24.0 million in gross proceeds to fund working capital and early-stage research into a neurotechnology device for sleep-related conditions. As of September 30, 2026, Indaptus held $30.6 million in cash, cash equivalents, and short-term investments, providing sufficient liquidity to support its anticipated operating expenses. The company also announced a strategic shift away from its Decoy20 clinical program to focus on new opportunities with long-term potential.